Highbridge Capital Management’s Travere Therapeutics TVTX Stock Holding History

Highbridge Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-65,146	Closed	-$1.47M	–	432
2018 Q4	$1.47M	Sell	65,146 -55,895	-46%	-$1.39M	0.04%	248
2018 Q3	$3.48M	Buy	+121,041	New	+$3.46M	0.08%	259
2017 Q2	–	Sell	-15,610	Closed	-$283K	–	1613
2017 Q1	$288K	Buy	15,610 +2,785	+22%	+$54.5K	﹤0.01%	1160
2016 Q4	$243K	Buy	+12,825	New	+$262K	﹤0.01%	1045
2016 Q2	–	Sell	-62,578	Closed	-$855K	–	1763
2016 Q1	$855K	Buy	+62,578	New	+$949K	0.01%	784
2015 Q4	–	Sell	-23,032	Closed	-$460K	–	1819
2015 Q3	$467K	Buy	+23,032	New	+$682K	0.01%	1051

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Highbridge Capital Management's TVTX Position: Q1 2019 in Review

Highbridge Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 65,146 shares — an estimated $1.47M sold.

Highbridge Capital Management first reported a position in TVTX in Q3 2015 and held it in 6 quarters. The position peaked at $3.48M in Q3 2018. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

Highbridge Capital Management reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
Highbridge Capital Management sold 65,146 Travere Therapeutics shares in Q1 2019, an estimated $1.47M.
Highbridge Capital Management first reported a position in Travere Therapeutics in Q3 2015 and held it in 6 quarters.
Highbridge Capital Management's Travere Therapeutics position peaked at $3.48M in Q3 2018.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on Highbridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.